Refractive Outcomes Utilizing Two SS-OCT Biometers for IOL Power Calculations

Last updated: January 29, 2025
Sponsor: The Eye institute of Utah
Overall Status: Active - Recruiting

Phase

N/A

Condition

Eye Disease

Eye Disorders/infections

Vision Loss

Treatment

N/A

Clinical Study ID

NCT06801678
12809-ZJZavodni
  • Ages > 21
  • All Genders

Study Summary

The purpose of this study is to evaluate and compare the potential refractive outcomes using the Argos 1.5 biometer in the surgical planning for cataract extraction to that obtained from IOLMaster 700. Both devices are used as standard of care in surgical planning optimization for patients undergoing cataract surgery.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • 21 years or older (Adult age)

  • Assessed to have Cataract Grade 1 and above per LOCS III or Wisconsin Grading scalein at least one eye.

  • Able to comprehend and sign the informed consent form.

  • Potential postoperative best corrected distance visual acuity (BCDVA) of 0.3 logMARor better and targeted post-op refraction to be emmetropia, based on theinvestigator expert medical opinion.

Exclusion

Exclusion Criteria:

  • No active ocular infection or inflammation

  • Unable to fixate due to nystagmus or other eye movement abnormality (e.g.,significant strabismus)

  • Contraindicated for pupil dilation (e.g., narrow angles, allergies) per medicaljudgement of the investigator.

  • Any ocular disease and/or condition that, in the investigator's clinical judgment,may put the subject at significant risk, may compromise study result or mayinterfere significantly with the subject's participation in the study.

Study Design

Total Participants: 50
Study Start date:
January 09, 2025
Estimated Completion Date:
February 22, 2025

Study Description

Cataract surgery is one of the most performed surgical procedures globally. The goal of the cataract surgeon is to implant an intraocular lens (IOL) with an appropriate IOL power to compensate for the refractive error and leave the patient emmetropic. The accurate measurement of ocular parameters is therefore critical for the effective calculation of IOL power, which directly impacts postoperative visual outcomes. However, accurate IOL power determination is influenced by several factors, including the measurement techniques employed and the specific biometers used in the process.

Optical biometry has become the gold standard for ocular measurements since the introduction of the IOLMaster (Carl Zeiss Meditec AG, Jena, Germany) in 2001. The IOLMaster 700 utilizes SWEPT Source OCT (SS-OCT) with a wavelength of about 1055 nm to generate a 2D OCT cornea-to-retina cross-section scan of the eye. This allows for the computation of all axial biometry measurements, including axial lengths (AL), central corneal thickness (CCT), anterior chamber depths (ACD), and lens thickness (LT).

A relatively newer biometer, Argos 1.5 is also non-invasive and based on SS-OCT technology for IOL power determination with a similar wavelength of 1060 nm ±10nm. However, the IOLMaster 700 uses a traditional axial length computation approach that relies on a single refractive index whiles Argos 1.5 uses a segmented axial length approach based on multiple refractive indices attributed to each ocular component often referred as True AL.

This study aims to evaluate and compare the potential refractive outcomes and biometric measurements of patients undergoing cataract surgery when using Argos 1.5 versus the IOLMaster 700 with the available formulas on each device. By analyzing these biometric measurements, we aim to uncover insights that could enhance our understanding of how different measurement techniques influence postoperative visual outcomes, ultimately contributing to improved patient care.

Connect with a study center

  • The Eye Institute of Utah

    Salt Lake City, Utah 84107
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.